- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Collaborators
- Suppliers
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- Research centres
- People
- Alistair Brown
- Anne-Laure Puaux
- Assoc Prof Joanna Groom
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Ethan Goddard-Borger
- Associate Professor Gemma Kelly
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor John Wentworth
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Kelly Rogers
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Matthew Ritchie
- Associate Professor Melissa Call
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Peter Czabotar
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Sandra Nicholson
- Associate Professor Seth Masters
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Tracy Putoczki
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Belinda Phipson
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gwo Yaw Ho
- Dr Hamish King
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Jim Whittle
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Nadia Davidson
- Dr Nadia Kershaw
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Rory Bowden
- Dr Samir Taoudi
- Dr Sarah Best
- Dr Saskia Freytag
- Dr Shabih Shakeel
- Dr Shalin Naik
- Dr Sheau Wen Lok
- Dr Stephin Vervoort
- Dr Yunshun Chen
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Mark Eaton
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor James McCarthy
- Professor James Murphy
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leanne Robinson
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Marco Herold
- Professor Marnie Blewitt
- Professor Melanie Bahlo
- Professor Melissa Davis
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Sant-Rayn Pasricha
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Papenfuss
- Professor Wai-Hong Tham
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Clinician-scientist training
- Undergraduate
- Student research projects
- A multi-pronged approach to targeting myeloproliferative neoplasms
- A new paradigm of machine learning-based structural variant detection
- A whole lot of junk or a treasure trove of discovery?
- Advanced imaging interrogation of pathogen induced NETosis
- Analysing the metabolic interactions in brain cancer
- Boosting the efficacy of immunotherapy in lung cancer
- Building a cell history recorder using synthetic biology for longitudinal patient monitoring
- Characterisation of malaria parasite proteins exported into infected liver cells
- Deciphering the heterogeneity of the tissue microenvironment by multiplexed 3D imaging
- Defining the mechanisms of thymic involution and regeneration
- Delineating the molecular and cellular origins of liver cancer to identify therapeutic targets
- Developing computational methods for spatial transcriptomics data
- Developing drugs to block malaria transmission
- Developing models for prevention of hereditary ovarian cancer
- Developing statistical frameworks for analysing next generation sequencing data
- Development and mechanism of action of novel antimalarials
- Discoveries in red blood cell production and function
- Discovery and targeting of novel regulators of transcription
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Dissecting mechanisms of cytokine signalling
- Doublecortin-like kinases, drug targets in cancer and neurological disorders
- Epigenetic biomarkers of tuberculosis infection
- Exploiting cell death pathways in regulatory T cells for cancer immunotherapy
- Exploiting the cell death pathway to fight Schistosomiasis
- Finding treatments for chromatin disorders of intellectual disability
- Functional epigenomics in human B cells
- How do nutrition interventions and interruption of malaria infection influence development of immunity in sub-Saharan African children?
- Human lung protective immunity to tuberculosis
- Improving therapy in glioblastoma multiforme by activating complimentary programmed cell death pathways
- Innovating novel diagnostic tools for infectious disease control
- Integrative analysis of single cell RNAseq and ATAC-seq data
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigation of a novel cell death protein
- Malaria: going bananas for sex
- Mapping spatial variation in gene and transcript expression across tissues
- Multi-modal computational investigation of single-cell communication in metastatic cancer
- Nanoparticle delivery of antibody mRNA into cells to treat liver diseases
- Naturally acquired immune response to malaria parasites
- Organoid-based discovery of new drug combinations for bowel cancer
- Organoid-based precision medicine approaches for oral cancer
- Removal of tissue contaminations from RNA-seq data
- Reversing antimalarial resistance in human malaria parasites
- Role of glycosylation in malaria parasite infection of liver cells, red blood cells and mosquitoes
- Screening for novel genetic causes of primary immunodeficiency
- Statistical analysis of single-cell multi-omics data
- Structural and functional analysis of epigenetic multi-protein complexes in genome regulation
- Structure, dynamics and impact of extra-chromosomal DNA in cancer
- Targeted deletion of disease-causing T cells
- Targeting cell death pathways in tissue Tregs to treat inflammatory diseases
- The cellular and molecular calculation of life and death in lymphocyte regulation
- The role of hypoxia in cell death and inflammation
- The role of ribosylation in co-ordinating cell death and inflammation
- Understanding Plasmodium falciparum invasion of red blood cells
- Understanding cellular-cross talk within a tumour microenvironment
- Understanding the genetics of neutrophil maturation
- Understanding the roles of E3 ubiquitin ligases in health and disease
- Unveiling the heterogeneity of small cell lung cancer
- Using combination immunotherapy to tackle heterogeneous brain tumours
- Using intravital microscopy for immunotherapy against brain tumours
- Using nanobodies to understand malaria invasion and transmission
- Using structural biology to understand programmed cell death
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Lilly Backshell
- Megan Kent
- Naomi Jones
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Wayne Cawthorne
- Wil Lehmann
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- Learning Hub
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
Deluge of DNA changes drives progression of fatal melanomas
20 March 2021
Melbourne researchers have revealed how melanoma cells are flooded with DNA changes as this skin cancer progresses from early, treatable stages through to fatal end-stage disease.
discover the DNA changes that occur as melanoma
progresses.
Using genomics, the team tracked DNA changes occurring in melanoma samples donated by patients as their disease progressed, right through to the time the patient died. This revealed dramatic and chaotic genetic changes that accumulated in the melanoma cells as the cancers progressed, providing clues to potential new approaches to treating this disease.
The research, published in Nature Communications, was led by Professor Mark Shackleton, Professor Director of Oncology at Alfred Health and Monash University; Professor Tony Papenfuss, who leads WEHI’s Computational Biology Theme and co-heads the Computational Cancer Biology Program at Peter MacCallum Cancer Centre; and Dr Ismael Vergara, a computational biologist at WEHI, Peter Mac and the Melanoma Institute Australia.
At a glance
- Genomics has been used to track DNA changes in melanoma samples donated by patients whose disease recurred and progressed after treatment.
- The research revealed that end-stage melanomas acquired dramatic and chaotic genetic changes that are associated with aggressive disease growth and treatment resistance.
- Understanding the genetic changes that drive melanoma growth and treatment resistance could lead to new approaches to treating this cancer.
Tracking a devastating cancer
progresses from early to late stages
Image: WEHI.TV
Melanoma – the third most commonly diagnosed cancer in Australia – is caused by damaging changes occurring in the DNA of skin cells called melanocytes, usually as a result of exposure to ultraviolet (UV) radiation from sunlight. These genetic changes enable uncontrolled growth of the cells, forming a melanoma. As the melanoma cells keep dividing, some accumulate even more DNA changes, helping them to grow even faster and spread, said Professor Shackleton.
“At early stages, melanomas can be cured with surgery. However, they sometimes recur and progress to more aggressive forms. While there are excellent new therapies in these contexts, for some patients this progressing disease is difficult to treat,” he said.
“We used DNA sequencing to document genetic changes that occurred as melanomas recurred and progressed in patients.”
The team obtained genome sequencing data from tumours that had been donated by these patients and fed it into a mathematical model. This revealed that, as melanomas progress, they acquire increasingly dramatic genetic changes that add substantially to the initial DNA damage from UV radiation that caused the melanoma in the first place, said Professor Papenfuss.
“Early-stage primary melanomas showed changes in their DNA from UV damage – akin to mis-spelt words in a book. These changes were enough to allow the melanoma cells to grow uncontrollably in the skin,” he said.
“In contrast, end-stage, highly aggressive melanomas, in addition to maintaining most of the original DNA damage, accumulated even more dramatic genetic changes. Every patient had melanoma cells in which the total amount of DNA had doubled – a very unusual phenomenon not seen in normal cells – but on top of that, large segments of DNA were rearranged or lost – like jumbled or missing pages in a book. We think this deluge of DNA changes ‘supercharged’ the genes that were driving the cancer, making the disease more aggressive.
“The genomes in the late-stage melanomas were completely chaotic. We think these mutations occur in a sudden, huge wave, distinct from to the gradual DNA changes that accumulate from UV exposure in form earlier-stage melanomas. The melanoma cells that acquire these chaotic changes seem to overwhelm the earlier, less-abnormal, slower growing cells,” Professor Papenfuss said.
New insights into melanoma
Professor Shackleton said the research provided an in-depth explanation of how melanomas change as they grow and may also provide clues about how melanoma could be treated.
“We mapped sequential DNA changes to track the spread of the disease in individual cases, creating ‘family trees’ of melanoma cells that grew, spread and changed over time in each patient. In early-stage melanomas in the skin, the DNA changes were consistent with UV-damage, while the changes we saw in later-stage melanoma were totally wild, and associated with increased growth and spread of the disease, and evasion of the body’s immune defences. We could also link some DNA changes to the development of treatment resistance,” he said.
The research also revealed key cancer genes that may contribute to the growth and spread of the melanoma.
“Many patients’ late-stage melanomas had damage to genes known to control cell growth and to protect the structure of DNA during cell growth and division. When these genes don’t work properly, cell growth becomes uncontrolled and the DNA inside cells becomes even more abnormal – it’s a snowball effect. The findings also suggest that therapies which exploit these damaging changes might be useful for treating late-stage melanoma,” Professor Shackleton said.
The study included tumour samples from Peter Mac’s Cancer tissue Collection After Death (CASCADE) program – in which patients volunteer to undergo a rapid autopsy following their death.
“Our whole team would like to extend our sincere gratitude to the patients and their families whose participation in CASCADE made this research possible. We hope that the insights we have gained will lead to better treatments for people with melanoma,” Professor Shackleton said.
The research was supported by the Lorenzo and Pamela Galli Charitable Trust, the Australian NHMRC, Pfizer Australia, veski, the Victorian Cancer Agency, a European Commission Horizon 2020 grant, the Victorian Institute of Forensic Medicine, Tobin Brothers Funerals, the Peter MacCallum Cancer Foundation, Bioplatforms Australia, the Melanoma Institute of Australia, Cancer Council of Victoria, the Victorian Cancer Biobank, the Melbourne Melanoma Project and the Victorian Government.
WEHI Authors: Dr Ismael Vergara, Mr Lachlan McIntosh, Dr Daniel Cameron, Professor Tony Papenfuss
Media inquiries
WEHI media team
M: +61 475 751 811
E: communityrelations@wehi.edu.au
Alfred media team
M: +61 438 187 529
E: L.Humphrys@alfred.org.au
Super Content:
Want to hear about our latest discoveries? Subscribe to our supporter newsletter, Illuminate.
Many of our researchers work with people who have been been impacted by a disease, for example patients and carers.
Connecting with members of the community helps researchers make discoveries that improve human health.
Computational biology has enabled our researchers to develop a new method to identify melanoma patients with improved rates of survival.
Bioinformatics combines mathematics, statistics and computer science to solve complex biological problems.
Genetic sequencing shows promise for matching people with rare cancers to the right treatments, according to a new clinical trial.